Alamar Biosciences Inc 's Quick Ratio

ALMR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth

Alamar Biosciences Inc 's Cash & cash equivalent grew by 287.16 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Alamar Biosciences Inc 's Quick Ratio to 8.94 a new company high.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Quick Ratio than Alamar Biosciences Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 0 to 448.

Explain Quick Ratio?
How much Cash & cash equivalents ALMR�s has?
What are ALMR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ALMR Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q2	Q1
Y / Y Current Liabilities Change	-	-	-	-	-
Y / Y Cash & cash equivalent Change	-	-	-	-	-
Quick Ratio MRQ	8.94	2.69	3.98	-	-
ALMR's Total Ranking	# 448	# 0	#	#	#
Seq. Current Liabilities Change	16.27 %	218.85 %	-	-	-
Seq. Cash & cash equivalent Change	287.16 %	115.27 %	-	-	-

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Laboratory Analytical Instruments Industry	# 3
Healthcare Sector	# 182
Overall Market	# 448

Quick Ratio Statistics
High	Average	Low
8.94	5.2	2.69
(Jun 30 2026)		(Mar 31 2026)

Financial Statements
Alamar Biosciences Inc 's Current Liabilities	$ 28 Millions	Visit ALMR's Balance sheet
Alamar Biosciences Inc 's Cash & cash equivalent	$ 250 Millions	Visit ALMR's Balance sheet
Source of ALMR's Sales		Visit ALMR's Sales by Geography

Cumulative Alamar Biosciences Inc 's Quick Ratio

ALMR's Quick Ratio for the trailling 12 Months

ALMR Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	-	-	-	-
Y / Y Cash & cash equivalent TTM Growth	-	-	-	-	-
Quick Ratio TTM	5.79	2.99	3.98	-	-
Total Ranking TTM	#	#	#
Seq. Current Liabilities TTM Growth	88.51 %	318.85 %	-	-	-
Seq. Cash & cash equivalent TTM Growth	264.36 %	215.27 %	-	-	-

Quick ratio ranking by company, industry and sector >> Back to ALMR Financial Strength Comparisons >> Go to Compare ALMR Quick Ratio to its Competitors

On the trailing twelve months basis ALMR Cash & cash equivalent more than doubled by 287.16 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Alamar Biosciences Inc 's Quick Ratio to 5.79, above ALMR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Laboratory Analytical Instruments industry 2 other companies have achieved higher Quick Ratio than Alamar Biosciences Inc . While overall ranking is unchanged compared to the previous 12 months at no. 0.

Explain Quick Ratio?
How much Cash & cash equivalents ALMR�s has?
What are ALMR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Laboratory Analytical Instruments Industry	# 3
Healthcare Sector	# 182
Within the Market	# 448

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.94	5.2	2.69
(Jun 30 2026)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Laboratory Analytical Instruments Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Alamar Biosciences Inc	8.94	$ 250.052 Millions	$ 27.960 Millions
Eyepoint Inc	7.80	$ 327.214 Millions	$ 41.943 Millions
Astrotech Corp	5.02	$ 11.334 Millions	$ 2.257 Millions
Scientific Industries Inc	4.92	$ 7.882 Millions	$ 1.602 Millions
Standard Biotools Inc	4.75	$ 270.026 Millions	$ 56.802 Millions
10x Genomics Inc	4.66	$ 552.058 Millions	$ 118.509 Millions
Pacific Biosciences Of California Inc	3.44	$ 236.873 Millions	$ 68.806 Millions
Cytek Biosciences Inc	2.83	$ 262.004 Millions	$ 92.698 Millions
Quanterix Corporation	1.86	$ 93.529 Millions	$ 50.373 Millions

Date modified: 2026-09-05T14:53:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.